Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 101 - 125 of 156 in total
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.
Investigational
TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.
Investigational
Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Withdrawn
CI-1040 has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Breast Neoplasms, Pancreatic Cancer, and Colorectal Cancer, among others.
Investigational
Experimental
A product from the iodination of MONOIODOTYROSINE. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE). [PubChem]
Experimental
GDC-0623 has been used in trials studying the treatment of Solid Cancers.
Investigational
Investigational
Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer).
Investigational
Experimental
Displaying drugs 101 - 125 of 156 in total